Article (Scientific journals)
L'etude clinique du mois. L'etude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prevention apres un infarctus du myocarde: entre deux idees de l'ideal.
Scheen, André
2006In Revue Médicale de Liège, 61 (1), p. 53-9
Peer reviewed
 

Files


Full Text
200601_13.pdf
Publisher postprint (445.06 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anticholesteremic Agents/therapeutic use; Cardiovascular Diseases/prevention & control; Cholesterol, LDL/blood/drug effects; Female; Heptanoic Acids/therapeutic use; Humans; Male; Middle Aged; Myocardial Infarction/prevention & control; Prospective Studies; Pyrroles/therapeutic use; Risk Factors; Simvastatin/therapeutic use; Single-Blind Method; Treatment Outcome
Abstract :
[en] The IDEAL ("Incremental Decrease in End Points Through Aggressive Lipid Lowering") study compared the effects of two strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction. In this prospective, randomized, open-label, blinded end-point evaluation trial, patients were randomly assigned to receive a high dose of atorvastatin (80 mg/day; n = 4439), or an usual dose of simvastatin (20 mg/day, titrated up to 40 mg/day if necessary; n = 4449). During treatment, mean LDL cholesterol levels were 104 mg/dl in the simvastatin group and 81 mg/dl in the atorvastatin group (p < 0.001). After a median follow-up of 4.8 years, no significant difference was observed in the primary outcome of major coronary events (defined as coronary death, confirmed nonfatal acute myocardial infarction, or cardiac arrest with resuscitation), but the risk of other composite secondary end points (i.e., major cardiovascular events, all cardiovascular events, all coronary events) was statistically reduced in the atorvastatin group compared to the simvastatin group. There were no differences in cardiovascular or all-cause mortality between the two groups. In conclusion, patients with myocardial infarction may benefit from intensive lowering of LDL cholesterol without an increase in noncardiovascular mortality or other serious adverse reactions.
Disciplines :
Cardiovascular & respiratory systems
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
L'etude clinique du mois. L'etude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prevention apres un infarctus du myocarde: entre deux idees de l'ideal.
Alternative titles :
[en] The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal
Publication date :
2006
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
61
Issue :
1
Pages :
53-9
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 26 March 2009

Statistics


Number of views
560 (1 by ULiège)
Number of downloads
549 (1 by ULiège)

Scopus citations®
 
10
Scopus citations®
without self-citations
4

Bibliography


Similar publications



Contact ORBi